🇺🇸 FDA
Patent

US 9932581

Compositions and methods for modulating apolipoprotein C-III expression

granted A61KA61K31/7088A61K31/713

Quick answer

US patent 9932581 (Compositions and methods for modulating apolipoprotein C-III expression) held by Ionis Pharmaceuticals, Inc. expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
50
CPC classes
A61K, A61K31/7088, A61K31/713, A61K47/549, A61K47/59